Matt Meyerson

Charles A. Dana Chair in Human Cancer Genetics, Dana-Farber Cancer Institute

Professor of Genetics and Medicine, Harvard Medical School

Director, Center for Cancer Genomics, Dana-Farber Cancer Institute

Dana Farber Cancer Institute

617-632-4377

Meyerson Lab

Publications

Major copy proportion analysis of tumor samples using SNP arrays.

Authors: Authors: Li C, Beroukhim R, Weir BA, Winckler W, Garraway LA, Sellers WR, Meyerson M.
BMC Bioinformatics 2008-04-21
View full abstract on Pubmed

Adding pathogens by genomic subtraction.

Authors: Authors: MacConaill L, Meyerson M.
Nat Genet 2008-04-01
View full abstract on Pubmed

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.

Authors: Authors: Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin WG.
Genes Dev 2008-04-01
View full abstract on Pubmed

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.

Authors: Authors: Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, Look AT, Kucherlapati R, Kern SE, Meyerson M, Neel BG.
Genes Chromosomes Cancer 2008-03-01
View full abstract on Pubmed

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Authors: Authors: Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ.
Proc Natl Acad Sci U S A 2008-02-12
View full abstract on Pubmed

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.

Authors: Authors: Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB.
Int J Oncol 2008-02-01
View full abstract on Pubmed

Modeling genomic diversity and tumor dependency in malignant melanoma.

Authors: Authors: Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA.
Cancer Res 2008-02-01
View full abstract on Pubmed

The T790M mutatation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Authors: Authors: Yun Ch, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ
Proc Natl Acad SCi USA 2008-01-01

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Authors: Authors: Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.
Cancer Res 2007-12-15
View full abstract on Pubmed

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Authors: Authors: Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR.
Proc Natl Acad Sci U S A 2007-12-11
View full abstract on Pubmed